Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists

被引：0
|
作者：
Nguyen, Jennifer
Patel, Jeetvan
Kang, Barinder
Yu, Channing
Sawhney, Amrita
Fallick, Mark
Gorritz, Magdaliz
Chen, Chi-Chang
Paltanwale, Queenie
Sun, Kainan
Shore, Neal D.
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] IQVIA Inc, Wayne, PA USA
[3] GenesisCare, Carolina Urol Res Ctr, Myrtle Beach, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17048
引用
收藏
页数：1
相关论文
共 50 条
  • [1] 177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy
    Clements, Sarah
    Tempesta, Daniel
    Jacene, Heather
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2022, 50 (03) : 213 - 214
  • [2] Patient characteristics, treatment patterns, and outcomes among early adopters of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617): A real-world United States (US) study.
    Wei, Xiao X.
    George, Daniel J.
    Patel, Jeetvan
    Nguyen, Jennifer
    Kang, Barinder
    Sawhney, Amrita
    Gorritz, Magdaliz
    Chen, Chi-Chang
    Paltanwale, Queenie
    Sun, Kainan
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 81 - 81
  • [3] Patient characteristics and overall survival with lutetium (Lu177) vipivotide tetraxetan (177Lu-PSMA-617): A real-world analysis of early adopters.
    George, Daniel J.
    Shore, Neal D.
    Nguyen, Jennifer
    Patel, Jeetvan
    Sawhney, Amrita
    Kang, Barinder
    Chen, Chi-Chang
    Gorritz, Magdaliz
    Wei, Xiao X.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [4] Possible Treatment Approach to an Extravasation of 177Lu-PSMA-617
    Schlenkhoff, Carl Diedrich
    Essler, Markus
    Ahmadzadehfar, Hojjat
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (08) : 639 - 640
  • [5] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [6] Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
    Sartor, Oliver
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (06) : 823 - 829
  • [7] Survey of Clinical Protocols for the Use of 177Lu-PSMA-617 in the United States
    Kuo, Phillip H.
    Covington, Matthew F.
    Lee, Daniel J.
    Wong, Terence Z.
    Pandit-Taskar, Neeta
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2024, 52 (03) : 208 - 211
  • [8] Comparison of day of treatment vs 1 day post-treatment Lu177 SPECT/CT images in patients treated with lutetium Lu 177 vipivotide tetraxetan
    Prasad, Vikas
    Laforest, Richard
    Kim, Hyun
    Gay, Hiram
    Michalski, Jeff
    Dehdashti, Farrokh
    Wahl, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [9] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [10] 177Lu-PSMA-617 Therapy in a Patient on Haemodialysis with End Stage Renal Failure
    MacFarlane, L.
    Eifer, M.
    Saghebi, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S248 - S248
12345